Profile data is unavailable for this security.
About the company
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
- Revenue in CAD (TTM)12.43bn
- Net income in CAD-636.18m
- Incorporated2013
- Employees20.27k
- LocationBausch Health Companies Inc2150 St. Elzear Blvd. West, LavalLAVAL H7L 4A8CanadaCAN
- Phone+1 (514) 744-6792
- Fax+1 (514) 744-6792
- Websitehttps://www.bauschhealth.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix Inc | 61.10m | -138.36m | 1.42bn | 267.00 | -- | 3.75 | -- | 23.25 | -1.09 | -1.09 | 0.5249 | 2.43 | 0.191 | 2.36 | 2.12 | 228,827.70 | -43.26 | -46.70 | -47.93 | -54.18 | 90.84 | 89.36 | -226.46 | -228.65 | 16.55 | -11.30 | 0.1509 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Harrow Inc | 154.15m | -33.58m | 1.52bn | 315.00 | -- | 25.88 | -- | 9.83 | -0.9508 | -0.9508 | 4.38 | 1.65 | 0.581 | 4.95 | 4.39 | 489,352.40 | -12.66 | -10.86 | -14.77 | -12.71 | 71.16 | 70.75 | -21.78 | -15.35 | 2.43 | -0.3518 | 0.7608 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 95.15m | -106.22m | 1.59bn | 154.00 | -- | 22.58 | -- | 16.69 | -1.17 | -1.17 | 1.04 | 0.7306 | 0.5308 | 0.6941 | 5.41 | 617,850.60 | -59.26 | -40.21 | -80.97 | -47.99 | 94.62 | -- | -111.64 | -374.75 | 2.52 | -10.25 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Tilray Brands Inc | 788.94m | -244.98m | 1.63bn | 2.65k | -- | 0.4664 | -- | 2.06 | -0.3334 | -0.3334 | 1.06 | 4.14 | 0.185 | 2.50 | 8.40 | 297,714.00 | -5.22 | -- | -5.72 | -- | 28.31 | -- | -28.19 | -- | 1.42 | -0.9071 | 0.0963 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 281.45m | -53.44m | 1.79bn | 497.00 | -- | -- | -- | 6.35 | -1.07 | -1.07 | 5.55 | -- | 0.3556 | 0.5679 | 5.56 | 566,303.60 | -6.75 | -27.55 | -8.35 | -36.82 | 99.41 | -- | -18.99 | -97.12 | 5.15 | -- | 0.5495 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Ligand Pharmaceuticals Inc | 133.48m | 42.14m | 1.90bn | 58.00 | 46.66 | 2.42 | 24.54 | 14.21 | 2.22 | 2.22 | 7.33 | 42.82 | 0.1643 | 0.4789 | 4.08 | 2,301,345.00 | 5.19 | 12.32 | 5.35 | 12.99 | 91.82 | 81.65 | 31.57 | 80.32 | 15.81 | -- | 0.00002 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Supernus Pharmaceuticals Inc | 630.16m | 5.24m | 1.93bn | 652.00 | 395.90 | 2.01 | 21.35 | 3.06 | 0.0883 | 0.0883 | 11.39 | 17.39 | 0.4831 | 0.9256 | 4.36 | 966,507.70 | 0.4016 | 4.95 | 0.5117 | 6.41 | 88.34 | 88.61 | 0.8314 | 12.84 | 1.69 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Endo Inc | 1.92bn | -2.60bn | 2.01bn | 3.00k | -- | -- | -- | 1.05 | -34.02 | -34.04 | 25.08 | -88.41 | -- | -- | -- | -- | -- | -- | -- | -- | 52.36 | -- | -135.65 | -- | 2.75 | 95.17 | 5.83 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 656.11m | 114.99m | 2.07bn | 246.00 | 18.62 | 3.84 | 14.82 | 3.15 | 1.95 | 1.95 | 11.19 | 9.48 | 0.8107 | 25.74 | 8.93 | 2,667,110.00 | 14.21 | 7.46 | 16.68 | 9.08 | 79.41 | 80.58 | 17.53 | 10.46 | 3.09 | 52.20 | 0.2571 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Bausch Health Companies Inc | 9.20bn | -471.00m | 2.12bn | 20.27k | -- | -- | 2.78 | 0.23 | -1.29 | -1.29 | 25.07 | -3.20 | 0.3539 | 1.88 | 4.79 | 453,971.40 | -1.95 | -2.74 | -2.43 | -3.31 | 70.80 | 71.59 | -5.51 | -9.78 | 0.8238 | 1.20 | 1.01 | -- | 7.79 | 0.884 | -163.11 | -- | 2.97 | -- |
| Amphastar Pharmaceuticals Inc | 712.89m | 166.52m | 2.33bn | 1.76k | 15.28 | 3.29 | 10.63 | 3.27 | 3.14 | 3.14 | 13.45 | 14.57 | 0.4968 | 2.85 | 6.04 | 404,821.70 | 11.71 | 9.42 | 13.54 | 11.56 | 54.68 | 47.83 | 23.56 | 15.23 | 2.63 | 7.42 | 0.4515 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Catalyst Pharmaceuticals Inc | 434.48m | 68.15m | 2.41bn | 167.00 | 38.09 | 3.96 | 23.03 | 5.55 | 0.5335 | 0.5335 | 3.71 | 5.14 | 0.7554 | 4.03 | 8.69 | 2,601,647.00 | 11.85 | 25.42 | 13.56 | 29.81 | 86.67 | 85.63 | 15.69 | 30.87 | 4.94 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Vericel Corp | 214.52m | 789.00k | 2.42bn | 314.00 | 2,606.56 | 9.91 | 406.99 | 11.27 | 0.0189 | 0.0189 | 4.46 | 4.97 | 0.624 | 4.41 | 4.97 | 683,184.70 | 0.2295 | -3.07 | 0.2595 | -3.50 | 70.42 | 67.87 | 0.3678 | -4.49 | 4.16 | -- | 0.0008 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Twist Bioscience Corp | 295.21m | -220.31m | 2.56bn | 919.00 | -- | 5.20 | -- | 8.66 | -3.81 | -3.81 | 5.12 | 8.39 | 0.4076 | 5.42 | 8.56 | 321,229.60 | -30.42 | -30.50 | -33.85 | -33.84 | 40.53 | 36.02 | -74.63 | -113.33 | 4.52 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Amneal Pharmaceuticals Inc | 2.60bn | -174.62m | 2.59bn | 7.70k | -- | -- | 28.10 | 0.9956 | -0.6224 | -0.6224 | 10.09 | -0.1857 | 0.7206 | 3.00 | 3.60 | 337,401.60 | -3.69 | -4.80 | -4.93 | -5.93 | 35.04 | 34.76 | -5.13 | -9.00 | 0.8165 | 1.24 | 1.00 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
Data as of Aug 23 2024. Currency figures normalised to Bausch Health Companies Inc's reporting currency: US Dollar USD
47.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Icahn Associates Holding LLCas of 19 Aug 2024 | 34.72m | 9.47% |
| Paulson & Co., Inc.as of 30 Jun 2024 | 26.44m | 7.21% |
| GoldenTree Asset Management LPas of 30 Jun 2024 | 22.44m | 6.12% |
| Nomura Securities Co., Ltd. (Private Banking)as of 30 Jun 2024 | 19.37m | 5.28% |
| National Bank Financial, Inc.as of 30 Jun 2024 | 15.64m | 4.27% |
| Healthcare of Ontario Pension Planas of 30 Jun 2024 | 13.00m | 3.54% |
| Hudson Bay Capital Management LPas of 30 Jun 2024 | 11.50m | 3.14% |
| RBC Global Asset Management, Inc.as of 30 Jun 2024 | 11.10m | 3.03% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 10.78m | 2.94% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 8.07m | 2.20% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
